Karyopharm's Q3 2025 Earnings Call: Contradictions Emerge on Myelofibrosis Data, Sales Force Strategy, Enrollment Timelines, and Market Positioning

Date of Call: November 3, 2025

Financials Results

• Revenue: $44.0M total revenue in Q3 2025, up 13.4% YOY; U.S. XPOVIO net product revenue $32.0M, up 8.5% YOY
• EPS: Net loss $33.1M, ($3.82) per share GAAP; management noted >50% of loss driven by below-the-line/noncash items (primarily noncash interest and $7.4M mark-to-market adjustments)

Guidance:

• Full-year 2025 total revenue guided to $140M–$155M
• U.S. XPOVIO net product revenue guided to $110M–$120M
• R&D + SG&A expenses lowered to $235M–$245M (from prior $240M–$250M)
• Gross-to-net provisions expected to remain near Q3 level (~27%) in Q4
• Management expects existing liquidity and anticipated revenues to fund operations into Q2 2026

Business Commentary:

* Myelofibrosis Trial Milestone: - Karyopharm Therapeutics completed enrollment in its Phase III SENTRY trial in frontline myelofibrosis, marking a pivotal moment. - This trial represents a significant opportunity to redefine the standard of care for patients with myelofibrosis through the combination of selinexor plus ruxolitinib. - The trial aims to establish a new paradigm for treating myelofibrosis and validate XPO1 inhibition's relevance in hematological malignancies.

• Financial Performance and Refinancing:
• Karyopharm reported total revenue of $44 million for Q3, up 13% year-over-year, with U.S. net product revenue growing 8.5% to $32 million.
• The company secured approximately $100 million in financial flexibility through comprehensive refinancing and capital restructuring, extending its cash runway into Q2 2026.

• These financial results reflect the company's profitable multi myeloma commercial organization and disciplined execution, even as expenses were reduced.

• Clinical Progress and Safety Data:

• The company's blinded safety data from the SENTRY trial showed promising results, including an extrapolated rate of Grade 3/4 anemia at approximately 26% for the combination, lower than ruxolitinib's 37%.
• The combination therapy also demonstrated decreased treatment-emergent adverse events leading to discontinuation, at approximately 5% to 7% compared to ruxolitinib's 6% to 11%.

• These findings suggest a potentially improved safety profile, which could enhance patient experience and reduce monitoring burdens.

• Commercial Strategy and Market Potential:

• Karyopharm is preparing for a potentially transformational commercial launch in myelofibrosis, with a target market of roughly 4,000 newly diagnosed patients annually.
• The company sees significant opportunity to redefine the standard of care in myelofibrosis, as evidenced by a survey indicating 75% of physicians' intent to treat with combination therapy.
• Karyopharm's existing commercial capabilities are well-positioned to drive rapid and successful uptake upon regulatory approval.

Sentiment Analysis:

Overall Tone: Positive

• Management called it "a very productive quarter" with "meaningful clinical progress and strengthened financial flexibility." Q3 revenue was $44M (+13.4% YOY); enrollment in Phase III SENTRY is complete with top-line data expected March 2026; the company secured ~ $100M of financial flexibility and extended cash runway into Q2 2026.

Q&A:

• Question from Peter Lawson (Barclays Bank PLC, Research Division): I guess first is just around the MF data that we're seeing March '26. If you could just kind of walk through what we should see if it's like SVR PFS and OS trends if that's going to be staged across other medical meetings in 2026. And then a follow-up question would just be around the size of the sales force. I know you've kind of talked about 80% overlap, but interested to see how many you would add or dedicate to MF and also the kind of the ex-U.S. strategy.
  Response: Top-line in March 2026 will report primary endpoints (SVR35 at week 24 and absolute TSS) plus key secondaries and safety; minimal commercial hires expected due to ~80% account overlap and academic coverage, and ex-U.S. launches will be via existing partners.

• Question from Edward Tenthoff (Piper Sandler & Co., Research Division): Congrats on all the progress both on the clinical side and financial side. Can you remind us, are there any milestones associated with data or warrants or things like that for the recent financial restructuring that could extend that capital beyond the second quarter? And are there any geographies where you don't currently have distributors in place for myelofibrosis?
  Response: There are no warrant or financing triggers tied to positive MF data that would extend the June/Q2 2026 runway; global partnerships are in place for most markets—Japan remains the primary market without a partner.

• Question from Colleen Hanley (Robert W. Baird & Co. Incorporated, Research Division): Congrats on all the progress. Hopeful for the baseline TSS number, 22.5%, I think you said, Reshma, quite a lot higher than what you had enrolled in the Phase I, I believe. And based on the data that you had at AACR in 2023, it actually looks like fairly similar response for TSS above and below 20, which could just be due to the small end, but just curious how you would expect that might impact the read-through from Phase I to the pivotal Phase III? ... And then in that same AACR update, it looks like there was some variability in response for platelet count above and below 200,000... curious if you have the baseline platelet count and what your kind of thoughts are on the activity based on platelet count.
  Response: Baseline TSS ~22.5 (excluding fatigue) is encouraging and supports read-through that the combination could meaningfully improve absolute TSS versus ruxolitinib; baseline platelet distribution (majority >200k) is typical and not expected to materially affect SVR35 or TSS outcomes.

• Question from Maurice Raycroft (Jefferies LLC, Research Division): Congrats on the progress. So, ASH abstracts are coming out pretty soon. Just confirming, it sounds like your Phase III baseline data is going to be at ASH. Can you talk more about what's in the abstract and then what is going to be at the conference? ... And maybe as a follow-up, for the slightly lower treatment-emergent adverse events leading to discontinuation for the 61 patients in the blinded safety review. Can you comment on whether that rate is mostly in line with what you're seeing for the full study?
  Response: The ASH release is an abstract-only showing baseline characteristics (subset ~320); full ITT/top-line efficacy and more granular data will be reported in March 2026; the blinded 61‑patient safety snapshot shows stable, low discontinuation rates over extended follow-up, suggesting most discontinuations occur early and do not accumulate.

• Question from Brian Abrahams (RBC Capital Markets, Research Division): Congrats on all the progress. I wanted to drill down a little bit more on some of the market research findings, in particular, the high 75% intent to treat with the combo in frontline MF. I'm curious if you could talk a little bit more about sort of the types of patients that you're hearing physicians would try on a combo. Ruxolitinib initially, whether or not some of the payer feedback maybe you've been getting the early payer feedback has been aligned with what you're hearing from physicians in terms of the degree of frontline use. And then with the space expected to evolve and more targeted treatments like mccarls and more targeted JAKs, what impact do you think that might have on the way selinexor is ultimately positioned should it be successful in Phase III?
  Response: Market research shows ~75% intent among community and academic physicians to use selinexor+rux in newly diagnosed intermediate-to-high risk patients with platelets >100k; positioning is an add-on to ruxolitinib (not a replacement), management does not anticipate payer pushback, and they view the space as receptive to combination innovation despite potential future targeted agents.

• Question from Jonathan Chang (Leerink Partners LLC, Research Division): Just regarding the commercial potential launch in myelofibrosis, can you discuss any relevant learnings from the multi myeloma experience?
  Response: Key learnings applied: use a lower dose (60 mg once weekly) and implement dual antiemetic use early to improve tolerability; combined with an established commercial footprint in community settings, these lessons support a rapid, well-tolerated MF launch.

Contradiction Point 1

Myelofibrosis Data and Expectations

It involves differing expectations and interpretations of the myelofibrosis data, which is crucial for investor expectations and company positioning.

What should we expect for myelofibrosis data (SVR, PFS, OS trends) in March 2026? - Peter Lawson(Barclays)

2025Q3: Top-line results are expected in March 2026. They will include SVR35 at week 24, absolute TSS, and other secondary endpoints like hemoglobin and disease modification, with more details to follow then. - Reshma Rangwala(CMO)

What is your biggest concern regarding the myelofibrosis clinical trial results, and how are you approaching the multiple major readouts expected next year? - Edward Tenthoff(Piper Sandler)

2025Q2: The endpoint was a decrease in spleen volume of at least 35% over placebo at 24 weeks. So that's the primary endpoint. - Reshma Rangwala(CMO)

Contradiction Point 2

Sales Force and Market Strategy

It involves the strategy for expanding the sales force and market penetration, which are key to company growth and revenue expectations.

What should we expect for myelofibrosis data in March 2026, including SVR, PFS, and OS trends? What is the sales force size for myelofibrosis, and what is the international market strategy? - Peter Lawson(Barclays)

2025Q3: There's a strong overlap with the current commercial structure, with minimal additions expected. The ex-U.S. strategy involves partnering with existing partners for launches and royalty revenues. - Sohanya Cheng(CCO)

What is your primary concern regarding the myelofibrosis readout, and how are you approaching multiple major readouts next year? - Edward Tenthoff(Piper Sandler)

2025Q2: We will have a new sales force dedicated to the MF study. We will have a dedicated sales force for that. And again, we'll probably start with around 20 people or so and maybe build from there. - Sohanya Cheng(CCO)

Contradiction Point 3

Myelofibrosis Study Enrollment Timeline and Dynamics

It involves differing expectations and reporting of the enrollment timeline and dynamics of the Myelofibrosis study, which could impact the company's research and development milestones and investor expectations.

What should we expect in March 2026 for myelofibrosis data, including SVR, PFS, and OS trends? What is the size of the MF sales force, and what's the strategy for ex-U.S. markets? - Peter Lawson (Barclays Bank PLC)

2025Q3: Enrollment is expected to complete in June-July 2025. - Reshma Rangwala(CMO)

What are your assumptions for achieving full enrollment in June and July? Will you issue a press release upon reaching the target enrollment? - Unidentified Analyst (Jefferies)

2025Q1: We are aligned with completing enrollment in the June-July timeframe. - Richard Paulson(CEO)

Contradiction Point 4

Market Positioning and Physician Intent to Treat with Selinexor Combo

It involves differing perspectives on the market positioning and physician intent to treat with the selinexor combo, which are critical for the company's commercial strategy and revenue projections.

Can you discuss the market research findings, physician intent to use the combo therapy, and payer feedback? How might targeted therapies impact selinexor's positioning? - Brian Abrahams (RBC Capital Markets)

2025Q3: The target patient is newly diagnosed intermediate to high-risk with >100,000 platelets. Market research shows 75% intent to prescribe a combo, with no expected payer pushback. - Sohanya Cheng(CMO)

What is driving utilization in multiple myeloma? What marketing synergies exist within the existing sales force? And if we receive positive myelofibrosis (MF) data, how would that accelerate sales efforts in MF? - Ted Tenthoff (Piper Sandler)

2025Q1: In multiple myeloma, we are positioned as a flexible oral option post anti-CD38 therapy or in patients not eligible for T-cell therapies. - Richard Paulson(CEO)